AbCellera

ABCLPhase 2

Vancouver, CanadaFounded 2012abcellera.com

AbCellera is a pioneer in AI-powered antibody discovery, operating a unique platform that integrates microfluidics, high-throughput screening, and machine learning to rapidly identify therapeutic antibodies from natural immune responses. The company's business model is primarily partnership-driven, collaborating with major pharmaceutical companies to advance drug candidates while also building its own pipeline. Key achievements include its critical role in the discovery of bamlanivimab for COVID-19 and its successful IPO in 2020. Its strategic direction focuses on expanding its internal pipeline, scaling its platform capabilities, and deepening its partnerships across multiple therapeutic areas.

Market Cap

$1.0B

Founded

2012

Employees

450-550

Focus

Biotech

ABCL · Stock Price

USD 3.406.14 (-64.36%)

Historical price data

AI Company Overview

Technology Platform

An integrated AI-powered antibody discovery platform combining proprietary high-throughput microfluidics for single-cell analysis with advanced machine learning algorithms to search and analyze natural immune systems.

Pipeline Snapshot

2 drugs in pipeline

Drug	Indication	Stage
ABCL635 + Placebo	Vasomotor Symptoms Associated With Menopause	Phase 1/2
ABCL575 + Placebo (Normal Saline 0.9%)	Healthy Volunteers	Phase 1

Funding History

Total raised: $598M

IPO$483MUndisclosedDec 11, 2020

Series B$105MOrbiMedMar 15, 2020

Series A$10MDCVC BioFeb 15, 2018

Opportunities

AbCellera has significant growth opportunities in expanding its internal proprietary pipeline, which offers full economics from any successful drugs.

Additionally, the increasing industry demand for complex antibody modalities (bispecifics, conditionally active) and targeting difficult proteins plays directly to the strengths of its AI-powered discovery platform, enabling new and deeper partnerships.

Risk Factors

Key risks include dependency on partners for pipeline progression and revenue, the high failure rate inherent in early-stage drug development for its internal programs, and intensifying competition in the AI-driven biotech space that could challenge its technological edge and market position.

Competitive Landscape

AbCellera competes with large pharma internal teams (e.g., Regeneron) and specialized AI-biotech firms like Absci and BigHat Biosciences. Its main differentiation is the full-stack integration of proprietary high-throughput microfluidics for data generation with purpose-built machine learning for analysis, creating a unique and validated discovery engine.

Publications

Patents

Pipeline